VIEKIRA XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
| US10201541 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US10201584 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10105365 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9333204 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9744170 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
Viekira Xr is owned by Abbvie.
Viekira Xr contains Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir.
Viekira Xr has a total of 22 drug patents out of which 2 drug patents have expired.
Expired drug patents of Viekira Xr are:
- US7148359
- US7364752
Viekira Xr was authorised for market use on 22 July, 2016.
Viekira Xr is available in tablet, extended release;oral dosage forms.
Viekira Xr can be used as treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin., treatment of hcv infection using dasabuvir, treatment of hcv infection using paritaprevir, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., treatment of hcv infection using ombitasvir.
Drug patent challenges can be filed against Viekira Xr from 19 December, 2018.
The generics of Viekira Xr are possible to be released after 02 January, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date:
Market Authorisation Date:
22 July, 2016Treatment:
Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...Dosage:
More Information on Dosage
VIEKIRA XR family patents
